Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Characterization of disease-propagating stem cells responsible for myeloproliferative neoplasm–blast phase
Xiaoli Wang, … , John Mascarenhas, Ronald Hoffman
Xiaoli Wang, … , John Mascarenhas, Ronald Hoffman
Published March 8, 2022
Citation Information: JCI Insight. 2022;7(8):e156534. https://doi.org/10.1172/jci.insight.156534.
View: Text | PDF
Research Article Oncology Stem cells

Characterization of disease-propagating stem cells responsible for myeloproliferative neoplasm–blast phase

  • Text
  • PDF
Abstract

Chronic myeloproliferative neoplasms (MPN) frequently evolve to a blast phase (BP) that is almost uniformly resistant to induction chemotherapy or hypomethylating agents. We explored the functional properties, genomic architecture, and cell of origin of MPN-BP initiating cells (IC) using a serial NSG mouse xenograft transplantation model. Transplantation of peripheral blood mononuclear cells (MNC) from 7 of 18 patients resulted in a high degree of leukemic cell chimerism and recreated clinical characteristics of human MPN-BP. The function of MPN-BP ICs was not dependent on the presence of JAK2V617F, a driver mutation associated with the initial underlying MPN. By contrast, multiple MPN-BP IC subclones coexisted within MPN-BP MNCs characterized by different myeloid malignancy gene mutations and cytogenetic abnormalities. MPN-BP ICs in 4 patients exhibited extensive proliferative and self-renewal capacity, as demonstrated by their ability to recapitulate human MPN-BP in serial recipients. These MPN-BP IC subclones underwent extensive continuous clonal competition within individual xenografts and across multiple generations, and their subclonal dynamics were consistent with functional evolution of MPN-BP IC. Finally, we show that MPN-BP ICs originate from not only phenotypically identified hematopoietic stem cells, but also lymphoid-myeloid progenitor cells, which were each characterized by differences in MPN-BP initiating activity and self-renewal capacity.

Authors

Xiaoli Wang, Raajit K. Rampal, Cing Siang Hu, Joseph Tripodi, Noushin Farnoud, Bruce Petersen, Michael R. Rossi, Minal Patel, Erin McGovern, Vesna Najfeld, Camelia Iancu-Rubin, Min Lu, Andrew Davis, Marina Kremyanskaya, Rona Singer Weinberg, John Mascarenhas, Ronald Hoffman

×

Figure 9

MPN-BP ICs originate from both the HSCs and MLPs within the MNCs of Pt 5.

Options: View larger image (or click on image) Download as PowerPoint
MPN-BP ICs originate from both the HSCs and MLPs within the MNCs of Pt 5...
(A) Human cell engraftment (% hCD45+ cells) and leukemic burden (% hCD45dimCD33+ or % hCD34+ cells) in the BM (left), spleens (middle), and PB (right) of P0 recipients 11–12 weeks after the transplantation of equal numbers of HSCs and MLPs sorted by FACS from Pt 5 PB sample. n each=3 mice. (B) Human cell engraftment (% hCD45+ cells) and leukemia cell burden (% hCD45dimCD33+ or % hCD34+ cells) in the BM (left), spleen (middle), and PB (right) of P1 recipients 9–10 weeks after the transplantation of BMCs collected from P0 recipients receiving purified HSCs or MLPs from Pt 5. HSC, n = 4 mice; MLP, n = 3 mice. Bars indicate the mean in A and B. Data are shown as mean ± SEM. *P < 0.05, **P < 0.01, *** P < 0.001 by ANOVA. Please note HSC grafts were capable of engrafting and generating a similar high level of leukemia cell burden in P2 recipients, as observed in P1 recipients. By contrast, MLPs were not capable of engrafting P2 recipients (data not shown).

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts